Association of TP53 intron 3, 16 bp duplication polymorphism with esophageal and gastric cancer susceptibility in Kashmir Valley

Oncology Research

Volumn 19, Issue 3-4, 2011, Pages 165-169

  Malik, Manzoor Ahmad ^a   Sharma, Kokil ^a   Goel, Shivangi ^a   Ali Zargar, Showkat ^b   Mittal, Balraj ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^b SHER I KASHMIR INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Esophageal and gastric cancer; Kashmir Valley; PIN3 Ins16bp polymorphism

Indexed keywords

DNA; PROTEIN P53;

ADULT; AGED; ALLELE; ARTICLE; CHI SQUARE DISTRIBUTION; CONTROLLED STUDY; DISEASE ASSOCIATION; ESOPHAGUS CANCER; FEMALE; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; INDIA; INTRON; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SMOKING; STOMACH CANCER;

EID: 79952398160     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504011X12935427587920     Document Type: Article

References (32)

1. Parkin, D. M.; Pisani, P.; Ferlay, J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int. J. Cancer 54:594-606; 1993.
2. Parkin, D. M. The role of cancer registries in cancer control. Int. J. Clin. Oncol. 13(2):102-111; 2008.
3. Khuroo, M. S.; Zargar, S. A.; Mahajan, R.; Banday, M. A. High incidence of oesophageal and gastric cancer in Kashmir in a population with special personal and dietary habits. Gut 33:11-15; 1992.
4. Siddiqi, M.; Kumar, R.; Fazili, Z.; Spiegelhalder, B.; Preussmann, R. Increased exposure to dietary amines and nitrate in a population at high risk of oesophageal and gastric cancer in Kashmir (India). Carcinogenesis 13: 1331-1335; 1992.
5. Siddiqiz, M.; Tricker, A. R.; Preussmann, R. The occur- rence of preformed N nitroso compounds in food samples from a high risk area of esophageal cancer in Kashmir, India. Cancer Lett. 39:37-43; 1988.
6. Malik, M. A.; Upadhyay, R.; Mittal, R. D.; Zargar, S. A.; Modi, D. R.; Mittal, B. Role of xenobiotic-metabolizing enzyme gene polymorphisms and interactions with environmental factors in susceptibility to gastric cancer in Kashmir Valley. J. Gastrointest. Cancer 40:26-32; 2009a.
7. Malik, M. A.; Upadhyay, R.; Modi, D. R.; Zargar, S. A.; Mittal, B. Association of NAT2 gene polymorphisms with susceptibility to esophageal and gastric cancers in the Kashmir Valley. Arch. Med. Res. 40:416-423; 2009b.
8. Feki, A.; Irminger-Finger, I. Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Crit. Rev. Oncol. Hematol. 52:103-116; 2004.
9. Hsieh, L. L.; Wang, P. F.; Chen, I. H.; Liao, C. T.; Wang, H. M.; Chen, M. C.; Chang, J. T. C.; Cheng, A. J. Characteristics of mutations in the p53 gene in oral squamous cell carcinoma associated with betel quid chewing and cigarette smoking in Taiwanese. Carcinogenesis 22:1497-1503; 2001.
10. Pietsch, E. C.; Humbey, O.; Murphy, M. E. Polymorphisms in the p53 pathway. Oncogene 25:1602-1611; 2006.
11. Siddique, M.; Sabapathy, K. Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene 25:3489-3500; 2006.
12. Pim, D.; Banks, L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int. J. Cancer 108:196-199; 2004.
13. Dumont, P.; Leu, J. I.; Della, III, P. A. C.; George, D. L.; Murphy, M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 33:357-365; 2003.
14. Medeiros, R.; Vasconcelos, A.; Costa, S.; Pinto, D.; Lobo, F.; Morais, A.; Oliveira, J.; Lopes, C. Linkage of angiotensin I-converting enzyme gene insertion/deletion polymorphism to the progression of human prostate cancer. J. Pathol. 202:330-335; 2004.
15. Pinto, D.; Vasconcelos, A.; Costa, S.; Pereira, D.; Rodrigues, H.; Lopes, C.; Medeiros, R. HER2 polymorphism and breast cancer risk in Portugal. Eur. J. Cancer Prev. 13:177-181; 2004.
16. Santos, A. M.; Sousa, H.; Pinto, D.; Portela, C.; Pereira, D.; Catarino, R.; Duarte, I.; Lopes, C.; Medeiros, R. Linking TP53 codon 72 and P21 nt590 genotypes to the development of cervical and ovarian cancer. Eur. J. Cancer 42: 958-963; 2006.
17. Olivier, M.; Eeles, R.; Hollstein, M.; Khan, M. A.; Harris, C. C.; Hainaut, P. The IARC TP53 database: New online mutation analysis and recommendations to users. Hum. Mutat. 19:607-614; 2002.
18. Gemignani, F.; Moreno, V.; Landi, S.; Moullan, N.; Chabrier, A.; Gutierrez-Enriquez, S.; Hall, J.; Guino, E.; Peinado, M. A.; Capella, G.; Canzian, F. A. TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 23:1954-1956; 2004.
19. Wu, X.; Zhao, H.; Amos, C. I.; Shete, S.; Makan, N.; Hong, W. K.; Kadlubar, F. F.; Spitz, M. R. p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J. Natl. Cancer Inst. 94:681-690; 2002.
20. Costa, S.; Pinto, D.; Pereira, D.; Rodrigues, H.; Cameselle-Teijeiro, J.; Medeiros, R.; Schmitt, F. Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer 8:32; 2008.
21. Runnebaum, I. B.; Tong, X. W.; Konig, R.; Zhao, H.; Korner, K.; Atkinson, E. N.; Kreienberg, R.; Kieback, D. G.; Hong, Z. p53-based blood test for p53PIN3 and risk for sporadic ovarian cancer. Lancet 345:994; 1995.
22. Khaliq, S.; Hameed, A.; Khaliq, T.; Ayub, Q.; Qamar, R.; Mohyuddin, A.; Mazhar, K.; Qasim-Mehdi, S. P53 muta- tions, polymorphisms, and haplotypes in Pakistani ethnic groups and breast cancer patients. Genet. Test. 4:23-29; 2000.
23. Osorio, A.; Pollan, M.; Pita, G.; Schmutzler, R. K.; Versmold, B.; Engel, C.; Meindl, A.; Arnold, N.; Preisler-Adams, S.; Niederacher, D.; Hofmann, W.; Gadzicki, D.; Jakubowska, A.; Hamann, U.; Lubinski, J.; Toloczko-Grabarek, A.; Cybulski, C.; Debniak, T.; Llort, G.; Yannoukakos, D.; Díez, O.; Peissel, B.; Peterlongo, P.; Radice, P.; Heikkinen, T.; Nevanlinna, H.; Mai, P. L.; Loud, J. T.; McGuffog, L.; Antoniou, A. C.; Benitez, J. An evaluation of the polymorphisms Ins16bp and Arg72Pro in p53 as breast cancer risk modifiers in BRCA1 and BRCA2 mutation carriers. Br. J. Cancer 99: 974-977; 2008.
24. Miller, S. A.; Dykes, D. D.; Polesky, H. F. A simple salt- ing out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16:1215; 1988.
25. ICMR 2001-2003. Consolidated report of hospital based cancer registries. http://www.icmr.nic.in/ncrp/report-pop-hos-2001-03/cancer-h-based.htm.
26. Harris, A. L.; Mutant p53-the commonest genetic abnormality in human cancer? J. Pathol. 162:5-6; 1990.
27. Levine, A. J.; p53, the cellular gatekeeper for growth and division. Cell 88(3):323-331; 1997.
28. Shiao, Y. H.; Rugge, M.; Correa, P.; Lehmann, H. P.; Scheer, W. D. p53 alteration in gastric precancerous lesions. Am. J. Pathol. 144:511-517; 1994.
29. Weston, A.; Pan, C. F.; Ksieski, H. B.; Wallenstein, S.; Berkowitz, G. S.; Tartter, P. I.; Bleiweiss, I. J.; Brower, S. T.; Senie, R. T.; Wolff, M. S. p53 haplotype determination in breast cancer. Cancer Epidemiol. Biomarkers Prev. 6:105-112; 1997.
30. McBride, O. W.; Merry, D.; Givol, D. The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13). Proc. Natl. Acad. Sci. USA 83:130-134; 1986.
31. Mattick, J. S. Introns: Evolution and function. Curr. Opin. Genet. Dev. 4:823-831; 1994.
32. Mattick, J. S. RNA regulation: A new genetics? Nat. Rev. Genet. 5:316.47; 2004.